Navigation Links
Signal Genetics Announces Publication of Meta-Analysis of its Colon Cancer Test-Previstage™ GCC Confirming Prognostic Capabilities in Patients with Colon Cancer
Date:1/23/2012

NEW YORK, Jan. 23, 2012 /PRNewswire/ -- Signal Genetics, a privately held personalized medicine company focused on cancer, announced today the presentation of a paper entitled "Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis" at the 2012 American Society of Clinical Oncology Gastrointestinal Cancer Symposium held in San Francisco, CA January 21, 2012.  The data from the paper demonstrate the value of implementing Previstage testing in patients with colorectal cancer to identify those patients at risk of relapse.

The paper is the culmination of the work conducted by a team of researchers and  collaborators from several  centers, including:  Rhode Island Hospital, Brown University, University of Massachusetts  Medical School, University of North Carolina, Lahey Clinic, Brigham and Women's Hospital, British Columbia Cancer Agency and DiagnoCure Inc.  These researchers conducted a pooled individual data analysis on 310 patients to confirm whether molecular detection of GCC in Lymph Nodes indicates high risk of disease recurrence and poor survival in untreated stage II colon cancer.

GCC is a colon-specific biomarker normally found in gastrointestinal epithelium whose expression is preserved in primary and metastatic colorectal cancer cells. Studies to date have suggested that the presence of GCC gene expression in lymph nodes increased the likelihood of disease recurrence in stage II colon cancer patients, independent of traditional high risk features. The results of this study suggest that detection of GCC mRNA in lymph nodes is associated with risk of disease recurrence in stage II colon cancer patients not treated with adjuvant chemotherapy.  These findings are consistent with several other studies conducted over the past 10 years.

Based on GCC levels, the estimated 5 year recurrence risks were 11% and 32% for the low and high risk groups respectively, clearly showing that GCC is a strong prognostic marker that effectively stratifies patients between those that are essentially cured from those at risk of disease recurrence. Higher detection levels of GCC in lymph nodes is also significantly associated with increased risk of all-cause mortality, disease-specific survival, and disease-free survival. 

According to Joe Hernandez, President and CEO of Signal Genetics, "This paper represents further validation of GCC as a strong prognostic test that provides physicians and their patients an important insight that helps them make critical treatment decisions." 

About Signal Genetics.
Signal Genetics, the parent company of Myeloma Health, Respira Health, and CC Health, is a privately held personalized medicine genetic testing company focused on bringing novel insights to physicians and their patients with various types of cancer.  The goal of Signal Genetics is to provide information regarding disease status, stage, odds of relapse, predicting response to therapy, and prognosis through an array of proprietary tools to help guide physicians to the optimal treatment for each individual patient. Additional information is available at www.signalgenetics.com.


'/>"/>
SOURCE Signal Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signal Genetics Announces Launch of Next Generation Genetic Multiple Myeloma Predictive Testing Product-MyPRS Plus™
2. New Gene Study of ADHD Points to Defects in Brain Signaling Pathways
3. USPTO Issues Patent for CardioGenics Signal Amplification Technology
4. Signal Genetics and DiagnoCure Announce a US$13.3M Collaboration for the Commercialization of Previstage™ GCC Colorectal Cancer Staging Test
5. Signal Genetics Announces Commercialization Partnership with NeoGenomics Laboratories for Multiple Myeloma Gene Expression Test
6. Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area
7. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
8. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
9. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
10. Device Blocking Stomach Nerve Signals Shows Promise in Obesity
11. Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
Breaking Medicine News(10 mins):